{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:17:40Z","timestamp":1791357460678,"version":"4.3.1"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T00:00:00Z","timestamp":1557187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"DOI":"10.3389\/fpsyt.2019.00228","type":"journal-article","created":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T04:24:40Z","timestamp":1557203080000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":77,"title":["Use of Gabapentin in the Treatment of Substance Use and Psychiatric Disorders: A Systematic Review"],"prefix":"10.3389","volume":"10","author":[{"given":"Saeed","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Bachu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padma","family":"Kotapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahwish","family":"Adnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizwan","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umer","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hina","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Mahmood","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarij","family":"Zubair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iqra","family":"Qamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulshan","family":"Begum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,5,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013433","article-title":"Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis","volume":"7","author":"Houghton","year":"2017","journal-title":"BMJ Open"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.21897","article-title":"Gabapentin approvals, off-label use, and lessons for postmarketing evaluation efforts","volume":"319","author":"Wallach","year":"2018","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0708930105","article-title":"Pharmacological disruption of calcium channel trafficking by the \u03b12\u03b4 ligand gabapentin","volume":"105","author":"Hendrich","year":"2008","journal-title":"Proc Nat Acad Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.6.617","article-title":"Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"B6","first-page":"30","article-title":"Current diagnosis and treatment of anxiety disorders","volume":"38","author":"Bystritsky","year":"2013","journal-title":"Pharm Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1016\/j.annfar.2012.05.006","article-title":"Effects of a single 1200-mg preoperative dose of gabapentin on anxiety and memory","volume":"1","author":"Adam","year":"2012","journal-title":"Ann Fr Anesth Reanim"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2010.00826.x","article-title":"Gabapentin does not reduce preoperative anxiety when given prior to total hip arthroplasty","volume":"11","author":"Clarke","year":"2010","journal-title":"Pain Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.4103\/0253-7613.121368","article-title":"Effect of melatonin and gabapentin on anxiety and pain associated with retrobulbar eye block for cataract surgery: a randomized double-blind study","volume":"45","author":"Khezri","year":"2013","journal-title":"Indian J Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-012-2251-x","article-title":"A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors","volume":"136","author":"Lavigne","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1213\/01.ANE.0000152010.74739.B8","article-title":"Preoperative gabapentin decreases anxiety and improves early functional recovery from knee surgery","volume":"100","author":"M\u00e9nigaux","year":"2005","journal-title":"Anesth Analg"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199908000-00010","article-title":"Treatment of social phobia with gabapentin: a placebo-controlled study","volume":"19","author":"Pande","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200008000-00011","article-title":"Placebo-controlled study of gabapentin treatment of panic disorder","volume":"20","author":"Pande","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/0269881103017002006","article-title":"Effects of gabapentin on anxiety induced by simulated public speaking","volume":"17","author":"Quevedo","year":"2003","journal-title":"J Psychopharmacol"},{"key":"B15","first-page":"203","article-title":"Gabapentin premedication: assessment of preoperative anxiolysis and postoperative patient satisfaction","volume":"61","author":"Tirault","year":"2010","journal-title":"Acta Anaesthesiol Belg"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3126\/hren.v11i3.9642","article-title":"Effect of gabapentin premedication on preoperative anxiety and postoperative pain","volume":"11","author":"Pathak","year":"2013","journal-title":"Health Renaiss"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s12630-013-9890-1","article-title":"Gabapentin reduces preoperative anxiety and pain catastrophizing in highly anxious patients prior to major surgery: a blinded randomized placebo-controlled trial","volume":"60","author":"Clarke","year":"2013","journal-title":"Can J Anesth"},{"key":"B18","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.4103\/0019-5545.196976","article-title":"Clinical practice guidelines for obsessive-compulsive disorder","volume":"59","author":"Reddy","year":"2017","journal-title":"Indian J Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.mayocp.2017.06.022","article-title":"Management of obsessive-compulsive disorder","volume":"6","author":"Seibell","year":"2014","journal-title":"F1000prime Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-007-0798-z","article-title":"Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder","volume":"258","author":"\u00d6nder","year":"2008","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"B21","article-title":"Diagnostic and statistical manual of mental disorders (DSM-5\u00ae)","volume-title":"Am Psychiatr Publ","year":"2013"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/humu.23272","article-title":"DeepBipolar: identifying genomic mutations for bipolar disorder via deep learning","volume":"38","author":"Laksshman","year":"2017","journal-title":"Hum Mutat"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2190\/PM.43.3.e","article-title":"Adjunctive treatment with gabapentin in bipolar patients during acute mania","volume":"43","author":"Astaneh","year":"2012","journal-title":"Int J Psychiatry Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/PCC.10r01097","article-title":"The clinical management of bipolar disorder: a review of evidence-based guidelines","volume":"13","author":"Connolly","year":"2011","journal-title":"Prim Care Companion CNS Disord"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/00131746-200609000-00002","article-title":"Predictors of relapse in bipolar disorder: a review","volume":"12","author":"Altman","year":"2006","journal-title":"J Psychiatr Pract"},{"key":"B26","article-title":"Predictors of relapse in bipolar disorder: a review","volume":"12","author":"Altman","year":"2006","journal-title":"J Psychiatr Pract"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0320","article-title":"A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder","volume":"67","author":"Vieta","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(98)00192-X","article-title":"Gabapentin as an adjunctive treatment in bipolar disorder","volume":"55","author":"Young","year":"1999","journal-title":"J Affect Disord"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n0408","article-title":"Clinical experience with gabapentin in patients with bipolar or schizoaffective disorder: results of an open-label study","volume":"60","author":"Cabras","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-979219","article-title":"Clinical experience using adjunctive gabapentin in treatment-resistant bipolar mixed states","volume":"32","author":"Perugi","year":"1999","journal-title":"Pharmacopsychiatry"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(00)00514-9","article-title":"Adjunctive gabapentin treatment of bipolar disorder","volume":"15","author":"Vieta","year":"2000","journal-title":"Eur Psychiatry"},{"key":"B32","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1034\/j.1399-5618.2002.01211.x","article-title":"Gabapentin augmentation therapy in bipolar depression","volume":"4","author":"Wang","year":"2002","journal-title":"Bipolar Disord"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3956(98)00010-7","article-title":"An open label study of gabapentin in the treatment of acute mania","volume":"32","author":"Erfurth","year":"1998","journal-title":"J Psychiatr Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3109\/10401239909147073","article-title":"Gabapentin as an adjunct to standard mood stabilizers in outpatients with mixed bipolar symptomatology","volume":"11","author":"Sokolski","year":"1999","journal-title":"Ann Clin Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.1999.10113.x","article-title":"Gabapentin in the acute treatment of refractory bipolar disorder","volume":"1","author":"Altshuler","year":"1999","journal-title":"Bipolar Disord"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2000.20305.x","article-title":"Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy 1","volume":"2","author":"Pande","year":"2000","journal-title":"Bipolar Disord"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200012000-00004","article-title":"A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders","volume":"20","author":"Frye","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/mpr.1359","article-title":"Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States","volume":"21","author":"Kessler","year":"2012","journal-title":"Int J Methods Psychiatr Res"},{"key":"B39","volume-title":"Clinician\u2019s guide to medications for PTSD","author":"Jeffreys","year":"2009"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.14.1837","article-title":"Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial","volume":"283","author":"Brady","year":"2000","journal-title":"JAMA"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.12.1982","article-title":"Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study","volume":"158","author":"Marshall","year":"2001","journal-title":"Am J Psychiatry"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C082","article-title":"Gabapentin and posttraumatic stress disorder","volume":"37","author":"Malek-Ahmadi","year":"2003","journal-title":"Ann Pharmacother"},{"key":"B43","first-page":"97","article-title":"The psychobiology of anxiolytic drugs: Part 1: Basic neurobiology","volume":"1","author":"Sandford","year":"2000","journal-title":"Pharmacology & therapeutics"},{"key":"B44","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4088\/PCC.v02n0307","article-title":"Gabapentin in the treatment of posttraumatic stress disorder","volume":"2","author":"Berigan","year":"2000","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/jts.20270","article-title":"Pharmacotherapy to prevent PTSD: results from a randomized controlled proof-of-concept trial in physically injured patients","volume":"20","author":"Stein","year":"2007","journal-title":"J Trauma Stress"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3109\/10401230109148960","article-title":"Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy","volume":"13","author":"Hamner","year":"2001","journal-title":"Ann Clin Psychiatry"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2015.0071","article-title":"Large-scale network dysfunction in major depressive disorder: a meta-analysis of resting-state functional connectivity","volume":"72","author":"Kaiser","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"B48","first-page":"26","article-title":"New approaches to the treatment of refractory depression","volume":"61","author":"Fava","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb00830.x","article-title":"A beneficial effect on mood in partial epilepsy patients treated with gabapentin","volume":"40","author":"Harden","year":"1999","journal-title":"Epilepsia"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(01)01206-9","article-title":"Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders","volume":"51","author":"Obrocea","year":"2002","journal-title":"Biol Psychiatry"},{"key":"B51","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3389\/fnbeh.2017.00182","article-title":"The neurobiological mechanism of chemical aversion (emetic) therapy for alcohol use disorder: an fMRI study","volume":"11","author":"Elkins","year":"2017","journal-title":"Front Behav Neurosci"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181aba6a4","article-title":"Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms","volume":"29","author":"Anton","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10101436","article-title":"Gabapentin combined with naltrexone for the treatment of alcohol dependence","volume":"168","author":"Anton","year":"2011","journal-title":"Am J Psychiatry"},{"key":"B54","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.drugalcdep.2005.10.008","article-title":"The acute effects of gabapentin in combination with alcohol in heavy drinkers","volume":"83","author":"Bisaga","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000088905.24613.ad","article-title":"Treatment of acute alcohol withdrawal with gabapentin: results from a controlled two-center trial","volume":"23","author":"Bonnet","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/agp085","article-title":"An open trial of gabapentin in acute alcohol withdrawal using an oral loading protocol","volume":"45","author":"Bonnet","year":"2009","journal-title":"Alcohol Alcohol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2008.00706.x","article-title":"A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia","volume":"32","author":"Brower","year":"2008","journal-title":"Alcohol Clin Exp Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1108","article-title":"Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial","volume":"68","author":"Furieri","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"B59","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1369-1600.2008.00133.x","article-title":"Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin","volume":"14","author":"Mason","year":"2009","journal-title":"Addict Biol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.11950","article-title":"Gabapentin treatment for alcohol dependence: a randomized clinical trial","volume":"174","author":"Mason","year":"2014","journal-title":"JAMA Int Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2006.00299.x","article-title":"A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm","volume":"31","author":"Myrick","year":"2007","journal-title":"Alcohol Clin Exp Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2009.00986.x","article-title":"A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal","volume":"33","author":"Myrick","year":"2009","journal-title":"Alcohol Clin Exp Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R751","article-title":"Gabapentin versus chlordiazepoxide for outpatient alcohol detoxification treatment","volume":"47","author":"Stock","year":"2013","journal-title":"Ann Pharmacother"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1097\/ADT.0b013e31812e6a3c","article-title":"Alcohol detoxification and relapse prevention using valproic acid versus gabapentin in alcohol-dependent patients","volume":"7","author":"Trevisan","year":"2008","journal-title":"Addict Disord Their Treat"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/14651858.CD002024.pub5","article-title":"Alpha 2-adrenergic agonists for the management of opioid withdrawal","volume":"5","author":"Gowing","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31822bb378","article-title":"Importance of gabapentin dose in treatment of opioid withdrawal","volume":"31","author":"Salehi","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2008.02248.x","article-title":"Effect of add-on gabapentin on opioid withdrawal symptoms in opium-dependent patients","volume":"103","author":"Kheirabadi","year":"2008","journal-title":"Addiction"},{"key":"B68","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/ADT.0000000000000127","article-title":"Gabapentin, pregabalin, and placebo in reducing opioid withdrawal symptoms in opioid-dependent individuals: a randomized-controlled trial","volume":"17","author":"Kheirabadi","year":"2018","journal-title":"Addict Disord Their Treat"},{"key":"B69","article-title":"The effects of gabapentin on methadone based addiction treatment: a randomized controlled trial","volume":"26","author":"Moghadam","year":"2013","journal-title":"Pak J Pharm Sci"},{"key":"B70","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1037\/a0033724","article-title":"Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure","volume":"21","author":"Sanders","year":"2013","journal-title":"Exp Clin Psychopharmacol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5812\/ircmj.18202","article-title":"Trial of tramadol plus gabapentin for opioid detoxification","volume":"17","author":"Ziaaddini","year":"2015","journal-title":"Iran Red Crescent Med J"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0114","article-title":"Gabapentin reduces cocaine use among addicts from a community clinic sample","volume":"65","author":"Raby","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"B73","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1360-0443.2005.00983.x","article-title":"A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence","volume":"100","author":"Berger","year":"2005","journal-title":"Addiction"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.07.009","article-title":"A randomized placebo-controlled trial of gabapentin for cocaine dependence","volume":"81","author":"Bisaga","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2006.07.003","article-title":"Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients","volume":"87","author":"Gonz\u00e1lez","year":"2007","journal-title":"Drug Alcohol Depend"},{"key":"B76","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.drugalcdep.2005.03.006","article-title":"Smoked cocaine discrimination in humans: effects of gabapentin","volume":"80","author":"Haney","year":"2005","journal-title":"Drug Alcohol Depend"},{"key":"B77","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/JCP.0000000000000062","article-title":"Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms","volume":"34","author":"Mancino","year":"2014","journal-title":"J Clin Psychopharmacol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2006.03.019","article-title":"Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence","volume":"85","author":"Heinzerling","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2011.03619.x","article-title":"Double-blind placebo-controlled evaluation of the PROMETA\u2122 protocol for methamphetamine dependence","volume":"107","author":"Ling","year":"2012","journal-title":"Addiction"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1177\/0269881109349837","article-title":"A controlled trial of flumazenil and gabapentin for initial treatment of methylamphetamine dependence","volume":"25","author":"Urschel","year":"2011","journal-title":"J Psychopharmacol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1151\/ASCP07414","article-title":"Marijuana dependence and its treatment","volume":"4","author":"Budney","year":"2007","journal-title":"Addict Sci Clin Pract"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.2174\/138161211796150846","article-title":"Pharmacological treatment of cannabis dependence","volume":"17","author":"Weinstein","year":"2011","journal-title":"Curr Pharm Des"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200923070-00001","article-title":"Pharmacotherapy for cannabis dependence","volume":"23","author":"Vandrey","year":"2009","journal-title":"CNS drugs"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2015.1858","article-title":"Prevalence of marijuana use disorders in the United States between 2001 and 2002 and 2012-2013","volume":"72","author":"Hasin","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1038\/npp.2012.14","article-title":"A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults","volume":"37","author":"Mason","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"B86","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/MLR.0b013e3181ca404e","article-title":"The rise and fall of gabapentin for bipolar disorder: a case study on off-label pharmaceutical diffusion","volume":"48","author":"Fullerton","year":"2010","journal-title":"Med Care"},{"key":"B87","first-page":"305","article-title":"Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders","volume":"43","author":"Chouinard","year":"1998","journal-title":"Can J Psychiatry"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02805968","article-title":"The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine","volume":"127","author":"Singh","year":"1996","journal-title":"Psychopharmacology"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpsyt.2019.00228\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T04:24:45Z","timestamp":1557203085000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpsyt.2019.00228\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,7]]},"references-count":88,"alternative-id":["10.3389\/fpsyt.2019.00228"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2019.00228","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,7]]},"article-number":"228"}}